Mirtazapină Aurobindo (Mirtazapine)

Mirtazapine works by blocking presynaptic α2‑adrenergic receptors, which increases the release of norepinephrine, and by antagonizing specific serotonin receptors (5‑HT2 and 5‑HT3). Its strong antihistamine activity also contributes to its therapeutic profile.

The appropriate dose of Mirtazapină Aurobindo is determined by the prescribing healthcare professional based on the patient’s clinical condition, response to therapy, and tolerability. Dosage adjustments are made individually and should follow the prescriber’s instructions.

Mirtazapine is classified as Pregnancy Category B, indicating that animal studies have not shown risk, but there are no adequate human studies. It should be used during pregnancy only if the potential benefit justifies the risk. Limited data are available for breastfeeding, so a risk‑benefit assessment is required.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details, and necessary import documentation.

Mirtazapine belongs to the NaSSA class, differing from SSRIs and SNRIs by its dual antagonism of specific serotonin receptors and strong antihistamine effect. This profile often results in pronounced sedation and appetite stimulation, which can be advantageous for patients with insomnia or weight loss, but may be less suitable for those concerned about weight gain.

Mirtazapină Aurobindo should be stored at room temperature, below 25 °C, in its original packaging. Protect the product from moisture and direct sunlight to maintain its stability and potency.

The medication is taken orally, usually once daily in the evening due to its sedative properties. It should be swallowed whole with water and not crushed or chewed unless otherwise directed by a healthcare professional.

Serious risks include the potential for agranulocytosis or severe neutropenia, severe allergic reactions such as Stevens‑Johnson syndrome, and the emergence or worsening of suicidal thoughts, particularly during the initial treatment period. Patients should be monitored closely for these events.

Mirtazapine is contraindicated in patients with known hypersensitivity to the drug or any of its components. It should also be avoided in individuals currently taking monoamine oxidase inhibitors (MAOIs) or those with a history of severe agranulocytosis. Caution is advised for patients with hepatic impairment or uncontrolled epilepsy.